Aims
The purpose of our work is to develop a method for the fluorine‑18 isotopic labeling of binimetinib for its evaluation as a potential selective tracer to monitor BRAF mutation. However, binimetinib exhibits two aromatic fluorine atoms located both on inactivated positions, making [18F]binimetinib radiosynthesis a strong radiochemistry challenge.